Personal CFO Solutions LLC Increases Stake in Amgen Inc. (NASDAQ:AMGN)

Personal CFO Solutions LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 4.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,787 shares of the medical research company’s stock after acquiring an additional 110 shares during the period. Personal CFO Solutions LLC’s holdings in Amgen were worth $619,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bank Julius Baer & Co. Ltd Zurich grew its holdings in shares of Amgen by 99,178.6% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 309,188,418 shares of the medical research company’s stock worth $68,646,013,000 after acquiring an additional 308,876,983 shares during the period. Moneta Group Investment Advisors LLC raised its stake in shares of Amgen by 83,875.6% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after purchasing an additional 7,532,031 shares during the last quarter. Norges Bank bought a new position in Amgen during the 4th quarter valued at about $1,351,778,000. Envestnet Asset Management Inc. raised its stake in Amgen by 216.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 2,690,718 shares of the medical research company’s stock valued at $228,997,000 after buying an additional 1,839,455 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Amgen by 158.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock valued at $774,791,000 after acquiring an additional 1,806,456 shares during the last quarter. Hedge funds and other institutional investors own 74.44% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, major shareholder Amgen Inc purchased 1,764,705 shares of the firm’s stock in a transaction on Tuesday, September 19th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $29,999,985.00. Following the completion of the purchase, the insider now owns 35,368,653 shares in the company, valued at approximately $601,267,101. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder Amgen Inc purchased 1,764,705 shares of the firm’s stock in a transaction on Tuesday, September 19th. The stock was acquired at an average price of $17.00 per share, with a total value of $29,999,985.00. Following the completion of the acquisition, the insider now owns 35,368,653 shares in the company, valued at approximately $601,267,101. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jonathan P. Graham sold 10,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $272.81, for a total transaction of $2,728,100.00. Following the sale, the executive vice president now directly owns 28,078 shares in the company, valued at $7,659,959.18. The disclosure for this sale can be found here. Insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent research reports. Oppenheimer raised their target price on Amgen from $290.00 to $300.00 and gave the stock an “outperform” rating in a report on Friday, October 20th. HSBC began coverage on Amgen in a research note on Wednesday, September 6th. They issued a “buy” rating and a $320.00 price objective on the stock. SVB Leerink raised shares of Amgen from a “market perform” rating to an “outperform” rating and increased their price target for the company from $267.00 to $318.00 in a report on Wednesday, October 11th. Mizuho boosted their price objective on shares of Amgen from $214.00 to $223.00 and gave the company a “neutral” rating in a research report on Monday, August 14th. Finally, Wells Fargo & Company boosted their price objective on Amgen from $265.00 to $320.00 in a report on Thursday, October 12th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $278.15.

Check Out Our Latest Report on Amgen

Amgen Price Performance

AMGN opened at $265.39 on Friday. The firm has a market capitalization of $142.03 billion, a PE ratio of 18.86, a price-to-earnings-growth ratio of 2.61 and a beta of 0.58. The company has a debt-to-equity ratio of 7.71, a current ratio of 2.86 and a quick ratio of 2.56. The business’s 50-day moving average is $269.59 and its two-hundred day moving average is $247.35. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $291.60.

Amgen (NASDAQ:AMGNGet Free Report) last released its quarterly earnings results on Tuesday, October 31st. The medical research company reported $4.96 earnings per share for the quarter, beating analysts’ consensus estimates of $4.65 by $0.31. Amgen had a net margin of 28.20% and a return on equity of 165.37%. The business had revenue of $6.90 billion for the quarter, compared to analysts’ expectations of $6.92 billion. During the same period last year, the business earned $4.70 EPS. The company’s revenue was up 3.7% compared to the same quarter last year. Research analysts anticipate that Amgen Inc. will post 18.65 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be issued a dividend of $2.13 per share. The ex-dividend date is Thursday, November 16th. This represents a $8.52 annualized dividend and a dividend yield of 3.21%. Amgen’s dividend payout ratio is presently 60.55%.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Read More

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.